Products and Pipeline
Partners and distributors
Press releases 2012
Press releases 2011
Press releases 2010
Press releases 2009
Press releases 2008
Press releases 2007
Press releases 2009
- 2009 -
MOBERG DERMA CLOSED TRANCHE 2 OF FINANCING
MOBERG DERMA REPORTS POSITIVE PHASE II RESULTS FOR K201 AGAINST ATOPIC ECZEMA
Moberg Derma AB reports today positive results from a phase II clinical study for K201 against atopic eczema. The study which included 30 patients with mild to moderate eczema showed that treatment with K201 resulted in statistically significant improvement of clinical skin condition, skin barrier and skin hydration. The study results also indicated that K201 can prevent growth of commonly occurring bacteria in eczema patients. K201 was very well tolerated.
MOBERG DERMA RECEIVES GRANT FROM VINNOVA FOR PHARMACEUTICAL PROJECT
The pharmaceutical company Moberg Derma has received a grant of SEK 4,2 million from Vinnova (The Swedish Governmental Agency for Innovation Systems). The grant will be used to develop an innovative patent-protected pharmaceutical product that will further strengthen the company’s position in the area of topical antifungals.
MOBERG DERMA SECURED SEK 35 MILLION IN NEW SHARE ISSUE
The pharmaceutical company Moberg Derma recently secured SEK 35 million in a new share issue. Both existing and new shareholders subscribed for shares in the issue. More than SEK 100 million has now been raised for its operations since the company was established in March 2006.
MOBERG DERMA SIGNS COMMERCIAL AGREEMENT FOR NAIL FUNGUS PRODUCT K101 WITH LEADING NORDIC OTC COMPANY
Moberg Derma AB today announces a license and co-promotion agreement with a leading Nordic OTC company for K101 - Moberg Derma’s novel treatment for nail fungus (onychomycosis). In the agreement, Moberg Derma will be responsible for supply of the product and promotion to prescribers, while its Nordic partner will be responsible for promotion to consumers. Financial terms are not disclosed but include up-front and milestone payments as well as royalty components.
MOBERG DERMA ENTERS LICENSE AND DISTRIBUTION AGREEMENT WITH MEDPHARM
Moberg Derma AB and MedPharm Ltd today announce a license and distribution agreement for the development, marketing and sales of new dermatology products that will combine Moberg Derma’s Kaprolac® platform with MedPharm’s MedSpray™ technology. According to the agreement, MedPharm will be eligible for royalty payments.
MOBERG DERMA ACQUIRES PHARMACEUTICAL PROJECTS FROM ZELMIC
Moberg Derma AB today announces the acquisition of two pharmaceutical projects in preclinical phase from Zelmic AB (Lund, Sweden). Zelmic will assist Moberg Derma in the future development of the projects. The two companies also agreed on a long term collaboration on future development projects. Financial terms were not disclosed.
Subscribe to information on Moberg Pharma
Contact Investor relations:
Magnus Persson, IR
Phone: +46 733 55 26 01
Peter Wolpert, CEO
Phone +46 8 522 307 00
Moberg Pharma AB (publ)
Gustavslundsvägen 42, 5 tr, SE-167 51 Bromma, Sweden
Phone: +46 8 522 30 700
© Moberg Pharma AB 2013